The Dermatology Digest

FEBRUARY 14, 2024

The regulatory submissions of nemolizumab in prurigo nodularis are based on data from the phase III OLYMPIA clinical trial program, which evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in patients with prurigo nodularis.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

Aesthetics Advisor

MARCH 10, 2024

Infants of mothers randomized to cut out eggs, milk, and fish were significantly less likely to have eczema even years later. Eczema, also known as atopic dermatitis, is a chronic inflammatory skin disease. Previously, I talked about the safety and efficacy of other, more natural treatments. But what about diet?

Eczema 36

Eczema Diet Dermatitis Document 36

The Dermatology Digest

JANUARY 15, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE) with limited systemic exposure, according to two studies presented at the 2024 Winter Clinical Dermatology Conference in Honolulu, Hawaii. The post New Research Supports the Safety and Efficacy of Delgocitinib in CHE appeared first on The Dermatology Digest.

Safety 36

Safety Eczema Dermatology Treatments 36

The Dermatology Digest

MAY 16, 2024

Emma Guttman-Yassky, MD, PhD , the Waldman Professor and Chair of Dermatology at Icahn Mount Sinai and the Mount Sinai Health System in New York City, has been awarded a new $6.6 NIH Grant to Study Dupilumab in Pediatric AA appeared first on The Dermatology Digest. PHOTO CREDIT: DermNet The post Mount Sinai Awarded $6.6M

Eczema 69

Eczema Dermatitis Safety Clinic 69

The Dermatology Digest

SEPTEMBER 26, 2024

The new data was presented at the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam. The safety profile was consistent with that previously reported, the study showed. Safety is not an issue. Improvements in itch, sleep, and QoL were also observed over time. We don’t see any conjunctivitis.

Dermatitis 74

Dermatitis Safety Management Eczema 74

The Dermatology Digest

DECEMBER 15, 2023

The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

Safety 36

Safety Dermatitis Dermatology Management 36

The Dermatology Digest

FEBRUARY 14, 2024

VTAMA cream also demonstrated highly statistically significant improvement in the proportion of patients with ≥75% improvement in the Eczema Area and Severity Index (EASI75) from baseline to Week 8 compared to patients on vehicle, a key secondary endpoint in the pivotal trials.

Dermatitis 74

Dermatitis Office Management Eczema 74

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. However, there are concerns about the safety of using retinol on younger skin due to the physiological differences between children’s and adults’ skin.

Retinol 80

Retinol Social Media Skincare Routine Skincare 80

The Dermatology Digest

DECEMBER 15, 2023

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36

Safety Dermatitis Dermatology Management 36

The Dermatology Digest

DECEMBER 20, 2023

Tim Raducha-Grace Named Chief Platform Officer at Zerigo Health Tim Raducha-Grace is the new Chief Platform Officer at Zerigo Health, a connected phototherapy platform that couples a handheld Narrow-band ultraviolet B (NB-UVB) light device with a smartphone app and team of care providers to allow patients to treat psoriasis and eczema at home.

Dermatology 36

Dermatology Surgery Eczema Office 36

The Dermatology Digest

DECEMBER 3, 2024

The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization in Great Britain for delgocitinib cream (Anzupgo, Leo Pharma) for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate.

Marketing 36

Marketing Eczema Safety Management 36

The Dermatology Digest

JANUARY 30, 2024

The Pediatric Dermatology Research Alliance (PeDRA) has awarded nearly $240K to support pediatric dermatology research across four competitive grant programs. The post And the Winners Are…PeDRA Announces 2023 Grant Recipients appeared first on The Dermatology Digest.

Partnerships 36

Partnerships Eczema Hospital Dermatology 36

Alison Bladh

JANUARY 1, 2025

Skin Conditions Conditions like eczema, psoriasis, or seborrheic dermatitis can irritate the skin around the brows, leading to hair loss. Journal of the American Academy of Dermatology. Dermatologic Therapy. Journal of Cosmetic Dermatology. Dermatology Clinics. Dermatology Clinics. K., & Charwe, S.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52

The Dermatology Digest

AUGUST 30, 2024

The approval is based on previously available human safety data and data from a well-controlled animal study in which ACAM2000 vaccine was shown to be effective in protecting against mpox virus exposure. The post FDA OKs Emergent’s mPox Vaccine appeared first on The Dermatology Digest.

Portfolios 74

Portfolios Tools Eczema Safety 74

The Dermatology Digest

MARCH 10, 2024

More than two-thirds of people with atopic dermatitis (AD) and darker skin tones treated with lebrikizumab showed improvements in skin clearance and itch relief, according to late-breaking results from a Phase 3 study are being presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego.

Skin Types 36

Skin Types Fitzpatrick Scale Dermatitis Safety 36

The Dermatology Digest

JANUARY 23, 2024

The research was presented by Jonathan I Silverberg, MD, Associate Professor of Dermatology and Director of Clinical Research and Contact Dermatitis at The George Washington University School of Medicine in Washington, DC, during the late breaker session at Maui Derm 2024. Safety was assessed throughout the study.

Dermatitis 36

Dermatitis Safety Sustainability Eczema 36

The Dermatology Digest

NOVEMBER 14, 2024

In addition, the Swiss approval is supported by the results from the head-to-head DELTA FORCE Phase 3 clinical trial, which evaluated the efficacy and safety of delgocitinib cream compared with oral alitretinoin capsules. The cream is fast-tracked by the U.S.

Marketing 36

Marketing Eczema Safety Clinic 36

The Dermatology Digest

JANUARY 14, 2024

The overwhelming majority of people with atopic dermatitis (AD) treated with investigational roflumilast cream 0.15% (Zoryve, Arcutis) showed a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks, according to new pooled analyses from two Phase 3 studies. Fully 91.5%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

MARCH 7, 2024

The drug demonstrated significant and clinically relevant improvements in itch, patient-assessed quality-of-life indicators, inflammation, and safety, with minimal side effects and strong patient tolerability when compared to baseline.

Safety 36

Safety Dermatitis Eczema Clinic 36

The Dermatology Digest

JANUARY 11, 2024

of atopic dermatitis (AD) patients using Vtama (tapinarof) cream, 1% achieved Eczema Area and Severity Index (EASI )75 in an integrated analysis of all the ADORING Program studies, Dermavant reports. Storrs Medical Dermatology Professor and Director of CLEAR Eczema Center, at the Oregon Health & Science University, in a news release.

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

The Dermatology Digest

MARCH 11, 2024

No new safety signals were observed in this trial. The Eczema Area and Severity Index (EASI)-75 score was also maintained in 76% of those receiving nemolizumab—both Q4W and Q8W—compared to 64% receiving a placebo.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

JANUARY 16, 2024

and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. The post Label Update: FDA Green Lights Dupilumab for AD Patients With Moderate-to-Severe Hand and Foot Involvement appeared first on The Dermatology Digest.

Dermatitis 36

Dermatitis Pharmaceutical Safety Eczema 36

The Dermatology Digest

APRIL 22, 2024

Adult atopic dermatitis (AD) patients previously treated with dupilumab (Dupixent, Regeneron and Sanofi) who received 400mg eblasakimab weekly achieved Eczema Area Severity Index (EASI) 90, and 66.7% Treatment was well-tolerated and no new safety signals were identified.

Pharmaceutical 36

Pharmaceutical Dermatitis Eczema Injections 36

The Dermatology Digest

DECEMBER 19, 2023

The primary endpoint of the clinical trial was safety and tolerability. Statistical significance was achieved for improvement in patient-reported eczema severity; the clinically relevant threshold of improvement by 4 or more points was met in six patients (75%).

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

MARCH 11, 2024

These are the main findings from part 2 of a phase 2b trial that was presented at the 2024 annual meeting of the American Academy of Dermatology in San Diego, CA. The post Sanofi’s OX40-ligand Blocker Produces High Durable Response Rates in AD With Quarterly Dosing appeared first on The Dermatology Digest.

Sustainability 36

Sustainability Dermatitis Safety Hospital 36

Eminence Organics

OCTOBER 31, 2023

Lavender oil is known to lessen redness and irritation caused by dry skin and eczema. Robinson says: “Heat and steam are known triggers for many dermatologic conditions, such as rosacea, melasma and eczema.” Pro tip: If you don’t have herbs or oils available, adding a couple of tea bags can help achieve the same results.

Facials 66

Facials Sebum Hydration Moisturization 66

The Dermatology Digest

SEPTEMBER 25, 2024

The findings were presented at at the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam. ” The post Upadacitinib Performs Well in Phase 3 Trials of Hard-to-treat Head and Neck AD appeared first on The Dermatology Digest. The upshot? 307) 67.8 (320) 320) 75.9 (323) 323) 4 to 7.2 severe) 10.5 (152)

Dermatitis 36

Dermatitis Dermatology Eczema Safety 36

US Dermatologt Partners

MARCH 27, 2024

Dermatology Partners in Cedar Park, Texas , “ Red light therapy is so new that the dermatologic community hasn’t even settled on one name for it. Improves psoriasis , rosacea , acne , and eczema side effects. Safety and Side Effects This procedure is considered safe. According to Dr. Jean Charles of U.S.

Therapy 41

Therapy Treatments Dermatology Collagen 41

First Derm

DECEMBER 26, 2023

Skin Conditions (Eczema, Psoriasis, Contact Dermatitis) as Causes of Dry, Itchy Scalp Various skin conditions can lead to a dry, itchy scalp: a. Eczema (Dermatitis): Symptoms : Red, itchy, scaly patches on the scalp. 7] Triggers and Aggravators Common for Eczema and Psoriasis : Stress, hormonal changes, and environmental factors.

Management 49

Management Dermatitis Eczema Consultations 49

Eminence Organics

OCTOBER 31, 2023

Lavender oil is known to lessen redness and irritation caused by dry skin and eczema. Robinson says: “Heat and steam are known triggers for many dermatologic conditions, such as rosacea, melasma and eczema.” Pro tip: If you don’t have herbs or oils available, adding a couple of tea bags can help achieve the same results.

Facials 64

Facials Sebum Hydration Moisturization 64

The Dermatology Digest

JANUARY 13, 2025

Proof-of-concept efficacy and safety data from a Phase1bstudy of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress. ” The post AD Pipeline Update:Target Enrollment Complete in Phase 2b Trial of Nectar’s Rezpegaldesleukin in AD appeared first on The Dermatology Digest.

Dermatitis 36

Dermatitis Clinic Eczema Therapy 36

The Dermatology Digest

OCTOBER 26, 2024

“These findings indicate that upadacitinib may address an unmet medical need in patients with moderate-to-severe AD who do not achieve an adequate response while taking dupilumab,” conclude researchers who were led by Christopher Bunick, MD, PhD, an Associate Professor of Dermatology at Yale University in New Haven, CT.

Treatments 36

Treatments Dermatitis Pharmaceutical Eczema 36

The Dermatology Digest

DECEMBER 21, 2023

This was first reported by study co-author Stuart Turvey, MBBS, DPHIL, FRCPC in 2017 in patients with an immune dysregulatory and hypereosinophilic syndrome characterized by severe eczema and asthma. New Research Highlights Tissue-Specific Roles of JAK Signaling appeared first on The Dermatology Digest.

Dermatitis 36

Dermatitis Eczema Safety Dermatology 36

The Dermatology Digest

JANUARY 8, 2024

Kimball, MD, MPH, a professor of Dermatology at Harvard Medical School and the President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center in Boston, in a news release. The post HS Pipeline Watch: Abbvie’s Lutikizumab Advances to Phase 3 in HS appeared first on The Dermatology Digest.

Medical 36

Medical Clinic Therapy Eczema 36

The Dermatology Digest

OCTOBER 5, 2023

“It all boils down to stress,” said Keira Barr, MD, who presented “Beauty & The Beast: Stress, Trauma, Skin Disease & A Somatic Approach to Healing,” during the “Mind Body Therapies as Treatment Strategy in Dermatology: What is the Evidence?” This [can trigger] or exacerbate conditions like psoriasis, acne, and eczema.

Safety 36

Safety Social Media Therapy Sun Protection 36

US Dermatologt Partners

JANUARY 24, 2024

Dermatology Partners in McKinney, Texas , “When people talk about psoriasis , they typically focus on the thickened skin plaques, the flakiness, dryness, itching, pain, and irritation associated with flare-ups of this condition. Dermatology Partners for tailored advice and effective management strategies. Dermatology Partners.

Management 36

Management Skin Health Medical Dermatology 36

The Dermatology Digest

DECEMBER 18, 2023

The new AD guidelines also: • Highlight the safety of the topical calcineurin inhibitors with typical usage once or twice daily. The Joint Task Force is a partnership between the American College of Allergy, Asthma, and Immunology (ACAAI) and the American Academy of Allergy, Asthma and Immunology. Suggest against elimination diets for AD.

Dermatitis 36

Dermatitis Partnerships Therapy Diet 36